Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]

  • Awaiting development
  • GID-TA11667
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of Inebilizumab within its marketing authorisation for treating myasthenia gravis ID6587